INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Alvotech (NASDAQ: ALVO) and Encourages Investors with Substantial Losses to Contact the Firm

Company Overview - Alvotech develops and manufactures biosimilars to increase access to biologic medicines [3] Allegations and Stock Impact - On November 2, 2025, Alvotech announced that the FDA issued a complete response letter for its AVT05 biosimilar application, citing deficiencies found during a July inspection of its Reykjavik manufacturing facility [4] - Following this announcement, Alvotech's stock fell by 34.4%, closing at $5.03 per share on November 3, 2025 [4] Investigation Details - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Alvotech, stemming from allegations of providing potentially misleading business information to the investing public [1][2]